(PARAMEDIC)

REFERENCE NO. 528.1

SUBJECT: MEDICAL CLEARANCE CRITERIA SCREENING

TOOL FOR SOBERING CENTER (SC)

PROCEDURE:

- 1. Paramedic shall assess and evaluate the patient using all the criteria listed below.
- 2. If ALL criteria are **Yes (Green)** triage patient to designated Sobering Center (SC), only if transport time is within 15 minutes.
- 3. If ANY criterion is **No** (**Red**) triage patient to the most accessible 9-1-1 receiving hospital.
- 4. MEDICAL CLEARANCE CRITERIA FOR <u>SC</u>

Provider Impression of Alcohol Intoxication	Yes □	No □
Verbalizes consent	Yes □	No □
Cooperative and does not require restraints	Yes □	No □
Ambulatory, does not require wheelchair and no focal neurological deficit	Yes □	No □
No emergent medical condition	Yes □	No □
Age ≥ 18 years old and <u><</u> 65 years	Yes □	No □
Heart Rate ≥60 and <u><</u> 120 beats per minute	Yes □	No □
Respiratory Rate ≥12 and <u><</u> 24 respirations per minute	Yes □	No □
Pulse Oximetry ≥94% on room air	Yes □	No □
SBP ≥100 and <180 mmHg	Yes □	No □
Best Glasgow Coma Score ≥14*	Yes □	No □
If diabetes, glucose ≥60 and <250mg/dL	Yes □	No □
No injury meeting TC criteria or guidelines	Yes □	No □
No complaint of: chest pain, SOB, Abdominal or pelvic pain, or syncope	Yes □	No □
No bleeding including any hemoptysis or GI bleed	Yes □	No □
Not on anticoagulants**	Yes □	No □
Not pregnant (known or suspected)	Yes □	No □
No bruising or hematoma above the clavicles	Yes □	No □
No intellectual or developmental disability	Yes □	No □
No loss of consciousness within 24 hours (syncopal or seizure)	Yes □	No □
EMS Personnel feel patient is stable for SC	Yes □	No □

EFFECTIVE: 10-01-20 REVISED: NEW SUPERSEDES: NEW PAGE 1 OF 1

^{*} Best GCS – upon initial assessment, an inebriated person may not have spontaneous eye opening without stimulation and may not be fully oriented which = GCS of 13. Upon secondary assessment, if eyes remain open with minimal confusion, GCS is 14 and meets criteria.

^{**} Common Anticoagulants: Warfarin/Coumadin, Clopidogrel/Plavix. Enoxaprin/Lovenox, Rivaroxaban/Xarelto, Dagigatran/Pradaxa, Apixaban/Eliquis, Edoxaban/Savaysa, and Fondaparinux/Arixta.